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Background: Tumour expression of selected microRNAs (miRs) correlates with cisplatin efficacy in multiple cancers. We
investigated the role of selected miRs in patients receiving cisplatin-based therapy for advanced urothelial carcinoma (UC).
Methods: RNA was extracted from formalin-fixed paraffin-embedded tumour from 83 advanced UC patients who received
cisplatin. A miR panel based on relevance for platinum sensitivity and UC was studied by quantitative reverse transcription
quantitative PCR (RT–qPCR). Association of progression-free survival (PFS) with miR expression was analysed using cox regression.
Selected TFs were chosen by association with the panel of miRs using the Transcription Regulation algorithm (GeneGo
MetaCoreþMetaDrug version 6.23 build 67496). Bladder cancer (BC) cell lines were used to investigate the previously described
role of miR-21 mediating cisplatin sensitivity.
Results: The 83 patients had a median PFS of 8 months. In multivariate analysis, higher levels of E2F1 (P¼ 0.01, HR:
1.95 (1.14, 3.33)), miR-21 (P¼ 0.01, HR: 2.01 (1.17, 3.45)) and miR-372 (P¼ 0.05, HR: 1.70 (1.00, 2.89)) were associated with a shorter
PFS. In the 8 BC cell lines, miR-21 was not shown to be necessary nor sufficient for modulating cisplatin sensitivity.
Conclusions: In metastatic UC patients treated with cisplatin-based therapy, high primary tumour levels of E2F1, miR-21 and miR-
372 are associated with poor PFS independent of clinical prognostic factors. The in vitro study could not confirm miR-21 levels role
in modulating platinum sensitivity.
In 2015, more than 72 000 new cases of urothelial carcinoma (UC)
were expected to be diagnosed in the United States, with 30% of
initial cases presenting with muscle-invasive disease (Siegel et al,
2015). Metastatic UC remains incurable in the vast majority of
patients, with a median progression-free survival (PFS) and overall
survival (OS) of B8 and 14 months, respectively, with front-line
cisplatin-based chemotherapy (von der Maase et al, 2005;
Sonpavde and Bellmunt, 2015). Cisplatin-based chemotherapy
induces an overall response rate of B50%, with select patients
obtaining sustained responses (Bajorin et al, 1999; Apolo et al,
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2013). In an updated report of the randomised trial comparing
methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) with
gemcitabine and cisplatin, survival at 5 years were 15.3% and 13%,
respectively (von der Maase et al, 2005). Identifying biological
factors predicting chemotherapy benefit would spare non-respon-
ders the toxic effects of chemotherapy, and direct them towards
novel therapies. Therefore, it is imperative to determine new
biomarkers to predict which patients demonstrate durable benefits
from platinum therapy.
MicroRNAs (miRs) are small, single-stranded non-coding
RNAs, which function as oncogenes or tumour suppressors by
exerting critical roles in RNA silencing and post-transcriptional
gene expression regulation (Guo et al, 2010; Bartel, 2004). They are
usually 21–55 nt and single-stranded RNAs. miRs are located in
intragenic and intergenic regions of the genome and can be
transcribed separately or with their host genes. The miR/RNA-
induced silencing complex connects to an mRNA target to degrade
the mRNA or to prevent translation of the mRNA. Hence,
miRNAs are key regulators and can modulate many biological
processes. Moreover, given their small size, miRs are likely to
be better preserved (compared with proteins and mRNA) in
formalin-fixed paraffin-embedded (FFPE) tissue and comparable
to expression in fresh frozen tissue (Dijkstra et al, 2012). miRNA
expression has been shown to be altered in UC and shown to
correlate with response to platinum drugs in multiple other
malignancies such as non-small-cell lung cancer, ovarian cancer
and bladder cancer (Yu et al, 2008; Zhang et al, 2008; Dyrskjot
et al, 2009; Guancial et al, 2014). In addition, transcription factors
(TFs) have critical upstream roles in upregulating genes mediating
carcinogenesis and therapy response (Wushou et al, 2014; Lee et al,
2015; Mukherjee et al, 2015). Thus, both miRs and TFs modify
gene expression downstream and upstream from the genes,
respectively. However, understanding the roles of these molecules
in modifying UC biology is in its infancy.
We hypothesised that a panel of miRs and TFs expressed in UC
tumour tissue may be associated with durable PFS in patients
receiving platinum therapy for metastatic UC.
We analysed archival FFPE tumour tissue derived from 83
patients treated with first-line platinum therapy for metastatic UC
through a time to event analysis and by examining extreme
responders within the cohort. We then tested the association of
miRs identified to be significant with sensitivity to cisplatin in a
panel of UC cell lines.
MATERIALS AND METHODS
Patients and tissue specimens. All tissue samples from patients
were collected at the time of biopsy by transurethral resection of
the bladder tumour or radical cystectomy (RC). A component
of transitional cell carcinoma was required. All patients were
required to have subsequently received first-line platinum-based
chemotherapy for locally advanced or metastatic UC. Informed
consent was obtained from each patient and institutional review
board approval was obtained from Dana-Farber Cancer Institute
before data acquisition and genetic analysis. Baseline clinicopatho-
logical characteristics, prognostic factors, response to chemotherapy
and clinical follow-up were retrospectively collected.
RNA extraction. The H&E stains were prepared on 4-mM sections
from the FFPE tissue blocks of tumours from all patients and a
subset of normal bladders. Pathology review was undertaken to
identify the percentage cellularity of the tumour, the size of the
tumour region of interest and the presence of benign cells. A cutoff
of 70% tumour cellularity was the benchmark for subsequent RNA
extraction and downstream reverse transcriptase (RT)–PCR.
The AllPrep DNA/RNA FFPE Kit (Qiagen, Germantown,
MD, USA) was utilised for the RNA extraction from FFPE
tumours (see in vitro section below for cell-lines studies). Purified
RNA was quantified utilising the Quant-iT RiboGreen assay
(Life Technologies, Carlsbad, CA, USA) over the concentration
range 1–100 ngml 1.
miR and TF selection. We completed a Pubmed literature search
to identify the most frequently cited miRs associated with the terms
bladder, cancer, and metastasis and cisplatin treatment
(Supplementary Table 1). MicroRNAs were only included if three
or more references were found to support its inclusion. In order to
determine what TFs may be associated with the panel of miRs, we
used the biological networks tool using the Transcription
Regulation algorithm (GeneGo MetaCoreþMetaDrug version
6.23 build 67496, Thompson Reuters, Life Sciences Research;
https://portal.genego.com/). The miRTarBase (Release 6.0 Septem-
ber 2015) was utilised to assess the miRNA–target interactions that
are experimentally validated. The E2F1 interaction with hsa-miR-
21-5p has been validated experimentally by reporter assay, western
blot and microarray, which together are characterised as strong
evidence of an interaction. We ran confirmatory analysis using
miRTarBase (Release 6.0 September 2015).
RT–PCR to assess miR and TF levels. For miR expression levels,
we utilised 100 ng of RNA in each RT reaction with the TaqMan
MicroRNA reverse transcription kit (Life Technologies) and
subsequent PCR with the TaqMan Universal PCR Master Mix
(Life Technologies), according to the manufacturer’s protocol.
Target-specific stem–loop precursor probes (see Supplementary
Table 2 for probe details) were utilised in the RT step instead of
random hexomers. Single-plex assays were set up for the 14 miRs
including RNU48, which was utilised as the endogenous small
RNA reference control.
For TF expression levels (selected based on network analysis
using miRNA results – see below in statistical analysis section), we
utilised 200 ng RNA input into 20 ml reverse transcription reaction
(High-Capacity cDNA Reverse Transcription Kit, Life Technolo-
gies), and 1ml of the subsequent cDNA product was transferred to
the Taqman PCR assay (Life Technologies). GAPDH was utilised
as the reference housekeeping gene.
Real-time PCR was performed on Applied Biosystems 7900HT
(Life Technologies, Thermo Fisher Scientific corporation, Foster
City, CA, USA; https://www.thermofisher.com) using standard
protocol. Results were analysed using the DDCt or comparative
Ct method. Ct values were calculated from the real-time
amplification curves, where the threshold was set at 0.02.
Statistical and bioinformatics analysis. Expression levels of TFs
and miRs were summarised using median and interquartile ranges.
TF and miR levels were dichotomised at the median.
Progression-free survival was defined as time from the start day
of treatment for metastatic disease to the date of progression or
death, whichever occurred first. Patients alive without progression
on the last date of follow-up were censored. For time to event
analysis, Kaplan–Meier estimate was used to summarise PFS.
Progression-free survival was considered as the best estimate
because it captures more directly the benefit of chemotherapy
while OS is affected by non-disease-related death (toxicity, co-
morbid conditions and others). An exploratory analysis of OS was
performed despite the limitation in the sample size and in the
number of events.
Cox regression model was used to assess the association of TF
and miR levels with PFS in both univariate analysis and
multivariate analysis, adjusting for Eastern Cooperative Oncology
Group (ECOG)-performance status (PS) and visceral metastasis.
The HR and 95% CI are provided as well. Likewise, treatment type
(M-VAC vs Cisplatin Gemcitabine) was also included as a
covariate in the analysis.
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Patients were then divided into pre-defined extreme outlier
groups based on PFS outcomes, where alive without progression at
12 months was considered good outcome and death or progressive
disease (PD) within 4 months poor outcome. Four months was
chosen as the cutoff to exclude patients that received less than two
cycles and to capture patients assessed for disease response that
showed PD at first evaluation. Patients with non-evaluable disease,
and patients who went off therapy due to toxicity were removed
from the analysis. Wilcoxon’s rank sum test was used to assess
association of miR and TF levels between the extreme responder
groups. An exploratory outcome analysis of miR-21, E2F1, EZH2
and SUZ12 expression in the TCGA was undergone (Cancer
Genome Atlas Research Network, 2014), as well as the association
of these markers with the molecular subtypes.
In vitro testing. The activity of cisplatin was evaluated in eight UC
cell lines to generate a dose–response curve and calculate the
concentration that inhibits growth by 50% (GI50): 647V, J82,
RT112, RT4, T24, TCC-SUP, UMUC3 and VMCUB1. Cells were
plated in 96-well plates at a density of 2500 cells per well and
allowed to adhere. Cells were subsequently treated with cisplatin at
indicated concentrations using phosphate-buffered saline as the
vehicle. Cells were grown for 72 h and cell viability assessed by Cell
Titer Glo (Promega, Promega Corporation, Madison, WI, USA)
according to the manufacturer’s guidelines using an Envision plate
reader. The GI50 was calculated by nonlinear regression using
Graphpad Prism (GraphPad Software, Inc., La Jolla, CA, USA).
Results represent the average and s.d. of at least three independent
experiments done in triplicate.
RNA was isolated using Qiagen miRNeasy Mini kit, and specific
miRs reverse transcribed using Applied Biosystems Taqman
MicroRNA Reverse Transcription kit and Gene Expression Assay.
Real-time PCR was performed using Applied Biosystems Taqman
Universal Master Mix II and run on ABI Quantstudio 6. The level
of miR-21 was normalised to the average of RNU44 and RNU48
snoRNAs.
To further evaluate the role of miR-21 in cisplatin sensitivity, we
measured drug sensitivity after upregulation of miR-21 in the cell
lines with the lowest expression levels of miR-21, or suppression of
miR-21 in the lines with the highest expression of miR-21.
Expression of precursor miR-21 (Genecopoeia, Rockville, MD,
USA) by lentiviral transduction resulted in increased levels of miR-
21 as measured by qRT–PCR relative to transduction with control
precursor miRNA. The effect of miR-21 suppression was assessed
by transduction with a lentivirus expressing antisense to miR-21
(Genecopoeia) or control. Viruses were generated by co-transfec-
tion into 293T cells with pVsVg and pDelta 8.9 using Transit-LT1
transfection reagent (Mirus Bio., Genecopoeia), and virus collected
48 h after transfection. Infections were done in the presence of
4mgml–1 polybrene and selected with either puromycin or
hygromycin. As antisense suppression of miR-21 does not
necessarily result in its degradation, we confirmed suppression
by a miR-21 reporter assay. Reporter construct for miR-21 was
purchased from Active Motif (Carlsbad, CA, USA), which
expresses luciferase with miR-21-binding sites in the 30-UTR. A
luciferase vector that lacks the 30-UTR was used as a control.
Transfections were done in 96-well format using Lipofectamine
2000 (Thermo Fisher Scientific corporation). Cells were collected
48 h after transfection and luciferase activity measured using Active
Motif Lightswitch Luciferase Assay kit. Results represent the
average and s.d. of three independent replicates.
RESULTS
Patient characteristics. We identified FFPE primary tumours of
83 patients who received first-line cisplatin-based chemotherapy
(Table 1) for metastatic UC, including patients with N1 disease.
The median PFS was 12 months and 43 patients experienced
objective disease progression or died.
Selection of miRNA for tumour tissue profiling. In silico data
mining of the literature identified a panel of 14 miRs: miR-21;
miR-106b; miR-10b; miR-146a; miR-146b; miR-371; miR-372;
miR-373; miR-1224; miR-1248; miR-200c; Let-7i; miR-27a; and
miR-26b (Supplementary Table 2).
RT–PCR for miRs and TFs in tumour tissue. We performed the
TaqMan-based real-time RT–PCR analysis to examine expression
levels of the 14 selected miRs in total RNA extracted from the
primary FFPE tumours of all 83 patients and 8 normal bladder
samples. Median dCt values and interquartile range were calculated
for each miR (Supplementary Table 3). miR-200c (5.95 (4.87,
6.87)) was the highest and miR-10b ( 1.22 ( 2.02, 0.005)) the
lowest expressed miR in the tumour tissue. Tumour expression of
TWIST1, FOXO3, RELA, E2F1 and SMAD4 was also measured in
the tumours. Median dCT values and interquartile range were
calculated for each TF (Supplementary Table 4).
Selection of miRNA and TFs for tumour tissue profiling. E2F1,
TWIST and RELA were selected due to their clinical significance in
bladder transitional cell carcinoma (Wushou et al, 2014; Lee et al,
2015; Mukherjee et al, 2015). All 3 were found in the top 20
statistically significant (Po0.05) TFs associated with the original
panel of 14 miRs with GScores 4100, utilising the Transcription
Regulation algorithm (GeneGo MetaCore, Thompson Reuters,
Life Sciences Research) with default settings.
Association of miR and TF tumour tissue expression with PFS
and OS. We next analysed the differential expression levels
Table 1. Patient characteristics
N Percentage (%)
Clinical stage at dx of muscle invasive disease
T1 1 1
T2–T3a 9 11
T3b 3 4
T4 5 6
Any T, Nþ 8 10
Any T, any M, Mþ 27 33
Unknown 30 36
Regimen
GC 32 39
MVAC 45 54
Unknown 6 7
ECOG-PS
0 46 55
1 32 39
Unknown 5 6
Visceral disease
No 44 53
Yes 33 40
Unknown 6 7
Response
CR 8 10
PR 37 45
SD 11 13
PD 8 10
Unknown 19 23
PFS
o4 months 8 10
49–12 months 29 36
Abbreviations: CR¼ complete response; dx¼diagnosis; ECOG-PS¼Eastern Cooperative
Oncology Group-performance status; GC¼gemcitabine and cisplatin; MVAC¼
methotrexate, vinblastine, doxorubicin and cisplatin; PFS¼progression free survival; PR¼
partial response; SD¼ stable disease.
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between the PFS groups adjusting for ECOG-PS status and
presence of visceral disease. We determined that increased levels of
miR-21 and miR-372 were the only statistically significant miRNAs
associated with poor PFS (P–value o0.05) on univariate and
multivariate analyses. The dCt median for each miR was utilised as
a dichotic threshold, and the associated statistical significance with
respect to PFS are shown in Table 2. Higher E2F1 – above the
median – was the only TF statistically associated with PFS
(P-valueo0.05), with higher levels conferring poorer outcomes.
The significant association of E2F1 with PFS in both univariate and
multivariable analyses adjusting for ECOG status and presence of
visceral disease is shown in Table 2.
When combining all three significant features, increased levels
of E2F1 (P¼ 0.01, HR: 1.95 (1.14, 3.33)), and high miR-21
(P¼ 0.01, HR: 2.01 (1.17, 3.45)) and miR-372 (P¼ 0.05, HR: 1.70
(1.00, 2.89)), were associated with a shorter PFS. Patients with
altered expression in all three molecular factors had a median PFS
of 2.5 months, while the median PFS for those with none of these
alterations had not been reached. Table 3 shows the role of miR-21,
miR-372 and the E2F1 on PFS in univariate and multivariate
analyses. The combination of high miR-21, miR-372 and E2F1 was
robustly associated with PFS on multivariate analysis (P¼ 0.004,
HR¼ 6.7 (1.84, 24.5)).
In the analysis of the association of miR-372, miR-21 and E2F1
with the extreme or outlier phenotype of PFS (progressed or died
within 4 months vs 4alive without progression at 12 months),
only miR-21 and E2F1 were marginally statistically significant
(Table 4). A PFS curve based on high tumour miRNA levels of
miR-21 (A), miR-372 (B), E2F1 (C) and combination of miR-21
and E2F1 (D) is shown in Figure 1A–D.
An exploratory multivariate analysis for association of OS
showed a trend of higher expression level of miR-21 (HR¼ 1.75
with 95% CI: 1.00–3.09, P¼ 0.05) and for E2F1 (HR¼ 1.57 with
95% CI: 0.89–2.77, P¼ 0.12) associated with higher risk of death
(data not shown).
Association of clinical variables with PFS. We included the type
of treatment (M-VAC vs Cisplatin Gemcitabine) as a covariate in
multivariable analysis, the associations of markers with outcome
remained and we did not observe a trend of MVAC improving PFS
(HR: 1.17 with 95% CI: 0.69, 1.99).
Exploratory analysis in TCGA. Levels of E2F1 have been
associated with prognosis in bladder cancer also with an aggregate
signature with EZH2 and SUZ2. The outcome analysis of
E2F1, EZH2 and SUZ12 expression in TCGA showed that these
3 genes are highly upregulated in tumours compared with 15
normal samples confirming its implication in bladder cancers.
Besides, all 3 gene expressions were strongly correlated each other.
The Pearson correlation between E2F1 and EZH2 was 0.66 and
between E2F1 and SUZ12 was 0.41. However, with the short
follow-up in TCGA being a significant confounding factor, the
association of these three genes with outcome was not consistent
with each other.
To follow, we looked for the association of EZH2 and outcome,
in our patients. An association was observed, but when we
Table 2. Association of miR-21, miR-372 and E2F1with PFS in univariate and multivariable analyses
N
Progression
or death
Median PFS
(months) P-value HR and 95% CI P-value HR and 95% CI
miR-21 0.009 0.01
p0.10 41 20 26 1.00 (reference) 1.00 (reference)
40.10 39 23 8 1.97 (1.18, 3.30) 2.01 (1.17, 3.45)
miR-372 0.03 0.05
p1.02 40 17 24 1.00 (reference) 1.00 (reference)
41.02 40 26 8 1.73 (1.04, 2.89) 1.70 (1.00, 2.89)
E2F1 0.01 0.01
p1.72 42 19 16 1.00 (reference) 1.00 (reference)
41.72 38 24 8 1.96 (1.18, 3.27) 1.95 (1.14, 3.33)
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; PFS¼progression-free survival.
Table 3. Evaluation of miR-21, miR-372, E2F1, and the combination of all three, on PFS in univariate and multivariate analyses
Univariate HR and 95% CI Multivariate HR and 95% CI
P-value oMedian 4Median P-value oMedian 4Median
miR-21 0.009 1 (reference) 1.97 (1.18, 3.30) 0.01 1 (reference) 2.01 (1.17, 3.45)
miR-372 0.03 1 (reference) 1.73 (1.04, 2.89) 0.05 1 (reference) 1.70 (1.00, 2.89)
E2F1 0.01 1 (reference) 1.96 (1.18, 3.27) 0.01 1 (reference) 1.95 (1.14, 3.33)
miR-21, miR-372 and E2F1 0.0004 1 (reference) 7.62 (2.46, 23.58) 0.004 1 (reference) 6.7 (1.84, 24.5)
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; PFS¼progression-free survival.
Table 4. Association of E2F1, miR-372 and miR-21 with the
extreme or outlier phenotype of PFS (progressed or died
within 4 months vs4alive without progression at 12 months)
N Median (q1, q3) P-value
E2F1 0.055
Progressed or died within 4 months 8  1.19 ( 1.69, 0.64)
Alive without progression at 12 months 29  1.98 ( 2.59, 1.50)
miR-372 0.11
Progressed or died within 4 months 8 1.54 (1.00, 1.70)
Alive without progression at 12 months 29 0.78 (0.22, 1.44)
miR-21 0.05
Progressed or died within 4 months 8 0.56 ( 0.24, 1.27)
Alive without progression at 12 months 29  0.25 ( 0.53, 0.38)
Abbreviations: PFS¼progression-free survival; TF¼ transcription factor. MicroRNA and TF
expression levels represented as ddCT values for PFS412 months ando4 months is shown
here.
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included EZH2, E2F1 and miR-21 in the model, only E2F1 and
miR-21 remained significant (data not shown).
The association of the markers studied with molecular subtypes
was also addressed. miR-21 was a differentially expressed maker,
but it was downregulated in mRNA cluster II (luminal). No
analysis was available with E2F1, EZH2 or SUZ2 in terms of
mRNA subtypes.
Finally, no platinum therapy data is available to correlate with
miR data in bladder TCGA, since the tissue analysed is obtained
from cystectomies and median follow-up is short.
Activity of cisplatin in UC cell lines. A range of inhibitory
concentrations (GI)50 were observed when we investigated the
activity of cisplatin in eight UC cell lines (Figure 2).
There was no correlation between miR-21 expression and GI50
(Supplementary Figure 1). In cell lines with relatively reduced
expression of miR-21 (RT-4, RT112, 647-V and VM-CUB1),
exogenous expression by lentiviral transduction resulted in
increased levels of miR-21 as measured by qRT–PCR relative to
transduction with a control precursor miRNA (Supplementary
Figure 2A). However, there was no subsequent effect on cisplatin
sensitivity (Supplementary Figures 2B and 3). In an analogous
fashion, suppression of miR-21 by transduction with a lentivirus
expressing antisense to miR-21 in cell lines with the highest miR-
21 expression (J82, T24, TCC-SUP and UMUC3) did not alter
cisplatin sensitivity (Supplementary Figure 3).
DISCUSSION
In our study of metastatic UC patients treated with cisplatin-based
therapy, tumour levels of E2F1 gene expression, and miR-21, and
miR-372 correlated with PFS independent of clinical prognostic
factors, including visceral metastasis and ECOG-PS. miRs have
been known to be differentially expressed in UC tissue and they
have been correlated with cancer development. However, the
mechanism of action of regulation of cancer development or
response to treatment is poorly understood. Certain miRs have
been shown to act as oncogenes and tumour suppressors. Each
miR is thought to target multiple mRNAs and each mRNA has
multiple miRs that target it. Owing to these duplications, it is
often difficult to identify a correlative relationship between the
expression of miRs and mRNAs. On the basis of the available
literature data, miR-21 is a relevant biological factor in multiple
malignancies and has a potential role in predicting chemosensi-
tivity (Saito et al, 2011; Wei et al, 2011; Akagi et al, 2013).
Consequently, we specifically focused on its role in predicting
outcomes in a clinical cohort of metastatic UC patients receiving
platinum and in sensitivity to cisplatin in vitro in bladder cancer
cell lines.
miR-21 has been shown to be upregulated in cancerous tissue,
and thought to be an oncogene. For example, it appears
upregulated during damage from radiation and helps repress
Cdc25A, which is involved in cell cycle control (de Oliveira et al,
2009). High levels of miR-21 have been extensively reported in
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Figure 2. Sensitivity of bladder cancer cell lines to cisplatin in vitro.
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multiple studies to be associated with outcomes in UC as well as in
other malignancies (Zhou et al, 2014). A recent focused meta-
analysis from 19 bladder cancer data sets identified three
upregulated (miR-141, miR-200c and miR-21) and five down-
regulated (miR-145, miR-125, miR-199a, let-7c and miR-99a) miRs
associated with OS (Zhou et al, 2015). Increased expression of
miR-21 has also been shown to confer resistance to platinum in
preclinical systems and appears prognostic in the post-operative
setting of non-small-cell lung cancer (Saito et al, 2011; Wei et al,
2011; Akagi et al, 2013). Thus, our observation of the association
of high miR-21 with shorter survival is consistent with these
previous reports. However, the sensitivity of UC cell lines to
cisplatin in vitro did not vary based on miR-21 levels, suggesting
that miR levels are prognostic but not predictive in the setting of
cisplatin-based chemotherapy for UC. Similar data exist for
prognostic impact of intrinsic subtypes (e.g., luminal, basal and
p53 type) of UC based on gene expression data and on the
PD-L1 immunohistochemical expression (Bellmunt et al, 2015),
although the predictive impact of these classifications is unclear
(Sjodahl et al, 2012; Cancer Genome Atlas Research Network,
2014; Choi et al, 2014; Damrauer et al, 2014). Emerging data also
support the predictive impact of alterations in DNA repair
genes (ATM, RB1, FANCC, ERCC2 or ERBB2) on response to
neoadjuvant platinum-based chemotherapy (Rosenberg et al, 2014;
Groenendijk et al, 2015; McConkey et al, 2015; Plimack et al,
2015). Interestingly, we have observed that miR-21 is found to be
downregulated in mRNA cluster II (luminal) suggesting its adverse
prognostic role.
miR-372, another of the miRs identified to be prognostic in
our study, has been previously shown to be involved in the
epithelial–mesenchymal transition (EMT), downregulation of
cyclin-dependent kinase (CDK)-2 and epigenetic regulation
(Subramanyam et al, 2011; Tian et al, 2011). One of the
mechanisms of activity of miR-372 appears to be the inhibition
of transforming growth factor-b-induced EMT of human epithelial
cells. miR-372 could be a non-invasive biomarker for prognosis
assessment in several tumour types (Tan et al, 2014; Tu et al, 2015;
Yu et al, 2015). For example, in colorectal cancer a distinct miR
expression signature on serum miRNA372 has been identified as a
biomarker predicting chemosensitivity (Zhang et al, 2014).
Among TFs, we selected to study E2F1, TWIST and RELA due
to their clinical significance in UC. Consistent with other cancers
(Alla et al, 2010; Gu et al, 2014), we observed a relationship
between cancer progression and the overexpression of E2F1 gene.
Of note, in patients with non-muscle invasive bladder cancer,
increased tumour recurrence and progression has been associated
with increased E2F expression (Santos et al, 2014). Also,
transcriptional changes of E2F1 with its upstream counterparts
EZH2, and SUZ12 predict bladder cancer aggressiveness, as well as
anticancer drug resistance (Lee et al, 2015). While the E2F1
interaction with hsa-miR-21-5p has been validated, the recent
discovery of EZH2 having a relevant role in bladder cancer is
biologically relevant to urothelial carcinogenesis. It has been
experimentally demonstrated that EZH2 and E2F1 form a
transcriptional complex co-localising at specific chromatin sites
to activate the downstream target genes. The mechanisms under-
lying EZH2–E2F1 complex for cancer progression and their
therapeutic potential await future studies. The exploratory analysis
in our cohort did not find an association between EZH2 and
outcome without being able to analyse its role on progression.
Our study is limited by a modest sample size of 83 patients and
the retrospective design. Second, it mainly addresses a clinical/
tissue correlation and the chemosensitivity was only tested in vitro.
Also, the analysis was done in samples from primary tumours and
not from metastatic sites. The panel of miRs studied may not have
included some significant miRs, which have been reported across
other studies, for example, we did not include miR-129, which was
found to be associated with better prognosis in a study of 106
bladder tumour samples (Dyrskjot et al, 2009), or miRNA-27a
associated with resistance in bladder cell lines (Drayton et al,
2014). In addition, the modest size of our data set may have
prevented us from detecting the significance of some miRs, for
example, miR-106b and miR-10b were found to be univariately
associated with outlying responses, but were not significant on
overall PFS analysis or multivariate analysis. Similarly, TWIST1
was significantly associated with outlying poor PFS on univariable
analyses, but not in a TTF analysis of the whole cohort, which may
be a function of sample size. Indeed, miR-106b, miR-10b and
TWIST1 have all been reported to exert prognostic impacts in
other studies (Sampath et al, 2009; Fritz et al, 2014; Wang et al,
2015). Finally, the dichotomisation of using the median for the
values is also a potential limitation and, perhaps another cut-point
may be more biologically and prognostically relevant.
To conclude, high tumour tissue miR-21 and low E2F1
conferred a significant negative impact on PFS in patients with
advanced UC receiving first-line cisplatin-based chemotherapy.
Given the small size and robustness of this molecule, miR can be
readily measured in archival FFPE tumour as well as plasma
samples. Unfortunately, our preclinical data could not confirm the
value of miR-21 in predicting sensitivity to cisplatin in vitro.
Taking into account all of these limitations, our analysis is
descriptive and exploratory and is unlikely to provide immediate
clinical benefit as a biomarkers. External validation with statistical
power, combining mir-21 with clinical variables known to have
a prognostic role in bladder cancer is the next step to follow.
We suggest that mir-21 may be included as a biological prognostic
factor in future studies.
Nevertheless, study of a larger panel of miRs including those
identified by us in a larger data set could provide an improved
molecular prognostic risk grouping, and potentially other miRs
predictive of benefit. Potentially, panels of TFs and miRs coupled
with other alterations at the gene level will improve the ability to
develop tailored therapy. A composite prognostic model consisting
of currently used clinical factors and a comprehensive molecular
panel accounting for the tumour and microenvironment will
enhance the interpretation of trials and progress towards the goal
precision medicine. Indeed, preliminary data have been reported
for the prognostic impact of a combination of clinicopathologic
factors and gene expression profile following RC for bladder cancer
(Riester et al, 2012).
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